{
  "title": "Long-Term Outcomes of Adjuvant Trastuzumab for 9 Weeks or 1 Year for -Positive Breast CancerTrastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13\u2009864 women in seven randomised trialsEarly breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upPan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOSSix versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG)6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trialEffect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2-positive breast cancer: the SOLD randomized clinical trialNine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER studyNine-week versus one-year trastuzumab for early human epidermal growth factor receptor 2-positive breast cancer: 10-year update of the ShortHER phase III randomized trialTrastuzumab and chemotherapeutics: drug interactions and synergiesFour-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831Cardiac toxicity events in the PHARE trial, an adjuvant trastuzumab randomised phase III studyLonger-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trialRisk of congestive heart failure in early breast cancer patients undergoing adjuvant treatment with trastuzumab: a meta-analysisAccess to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional surveyMetastatic behavior of breast cancer subtypes",
  "pmcid": "12507463",
  "features": {
    "sample_size": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "sample size"
      ],
      "examples": [
        {
          "match": "sample size",
          "context": "te of 3%, the estimated final sample size was 2168 patients (Supplement"
        }
      ]
    },
    "randomization": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "blinding": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "allocation_concealment": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "interaction_subgroup": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "stratification"
      ],
      "examples": [
        {
          "match": "stratification",
          "context": "method, and the study site as stratification factors. Chemotherapy consist"
        }
      ]
    },
    "variable_definitions": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "analysis_principles": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "intention-to-treat"
      ],
      "examples": [
        {
          "match": "intention-to-treat",
          "context": "rrent study were based on the intention-to-treat population. Survival between"
        }
      ]
    },
    "itt_details": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "intention-to-treat population"
      ],
      "examples": [
        {
          "match": "intention-to-treat population",
          "context": "rrent study were based on the intention-to-treat population. Survival between the groups"
        }
      ]
    },
    "software": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "sas",
        "sas, version 9.4"
      ],
      "examples": [
        {
          "match": "SAS, version 9.4",
          "context": "analyses were performed with SAS, version 9.4 (SAS Institute, Inc). CAPTION"
        },
        {
          "match": "SAS",
          "context": "formed with SAS, version 9.4 (SAS Institute, Inc). CAPTION:  FO"
        }
      ]
    },
    "error_measures": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "multiplicity_correction": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "multiple testing"
      ],
      "examples": [
        {
          "match": "multiple testing",
          "context": "s are 2-sided, unadjusted for multiple testing, and should be interpreted as"
        }
      ]
    },
    "normality_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "p_values": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "confidence_intervals": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "95% ci"
      ],
      "examples": [
        {
          "match": "95% CI",
          "context": "he upper limit of the 1-sided 95% CI used in the evaluation of non"
        }
      ]
    },
    "comparative_stats": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "non_parametric": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "assumption_checks": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "proportional hazards"
      ],
      "examples": [
        {
          "match": "proportional hazards",
          "context": "ank test or a univariable Cox proportional hazards regression model; hazard rati"
        },
        {
          "match": "proportional hazards",
          "context": "lated using a univariable Cox proportional hazards regression model. Interaction"
        },
        {
          "match": "proportional hazards",
          "context": "p were analyzed using the Cox proportional hazards regression model. Survival an"
        }
      ]
    },
    "survival_analysis": {
      "present": true,
      "count": 5,
      "unique_matches": [
        "kaplan-meier",
        "hazard ratio",
        "log-rank",
        "os"
      ],
      "examples": [
        {
          "match": "Kaplan-Meier",
          "context": "groups was compared using the Kaplan-Meier life table method and the log"
        },
        {
          "match": "log-rank",
          "context": "ier life table method and the log-rank test or a univariable Cox pro"
        },
        {
          "match": "hazard ratio",
          "context": "nal hazards regression model; hazard ratios (HRs) were calculated using"
        }
      ]
    },
    "regression_and_models": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "cox proportional"
      ],
      "examples": [
        {
          "match": "Cox proportional",
          "context": "og-rank test or a univariable Cox proportional hazards regression model; haz"
        },
        {
          "match": "Cox proportional",
          "context": "alculated using a univariable Cox proportional hazards regression model. Int"
        },
        {
          "match": "Cox proportional",
          "context": "group were analyzed using the Cox proportional hazards regression model. Sur"
        }
      ]
    },
    "reporting_guidelines": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "consort"
      ],
      "examples": [
        {
          "match": "CONSORT",
          "context": "tandards of Reporting Trials (CONSORT) reporting guideline for rand"
        }
      ]
    },
    "data_types": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "dependency": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "clustering": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "missing_data": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "dropout"
      ],
      "examples": [
        {
          "match": "dropout",
          "context": "f 1.3, 1-sided testing, and a dropout rate of 3%, the estimated fin"
        }
      ]
    },
    "effect_size": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "hazard ratio"
      ],
      "examples": [
        {
          "match": "hazard ratio",
          "context": "nal hazards regression model; hazard ratios (HRs) were calculated using"
        }
      ]
    },
    "post_hoc": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "post hoc"
      ],
      "examples": [
        {
          "match": "post hoc",
          "context": "This post hoc secondary analysis of the SOL"
        },
        {
          "match": "post hoc",
          "context": "accumulated.7 In the current post hoc secondary analysis of the tri"
        }
      ]
    },
    "baseline_reporting": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling_extra": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "excluded"
      ],
      "examples": [
        {
          "match": "excluded",
          "context": "s or neoadjuvant therapy were excluded.7 The trial protocol (Supplem"
        }
      ]
    },
    "systematic_review_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "diagnostic_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "model_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "domain_indicators": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    }
  }
}